← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksASBPEarnings History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

ASBP logoAspire Biopharma Holdings, Inc. (ASBP) Earnings History

Annual and quarterly earnings data from 2022 to 2024

TTM Net Income
-$32M
Net Loss
TTM EPS
$-0.64
Diluted
YoY EPS Growth
N/A
Net Margin
N/A
Profitability
Operating MarginN/A
Gross MarginN/A
ROEN/A
ROA-129.1%
Highest Annual Net Income-$359,071 (2023)
Highest Quarterly EPS$-0.00 (Q3 2023)
Consecutive Profitable Years0 years
Q3 2025
Net Income-$2M
EPS$-0.04
QoQ Growth+6.6%Solid

Loading earnings history...

EPS Growth Rates (CAGR)

Compound annual growth rate of diluted earnings per share

1-Year
N/A
N/M
3-Year
N/A
N/M
5-Year
N/A
N/M
10-Year
N/A
N/M

CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.

Profitability Analysis

Margin trends over time

View revenue breakdown →
YearGross MarginOperating MarginNet Margin
2024---
2023---
2022---
Gross Margin = Gross Profit ÷ Revenue
Operating Margin = Operating Income ÷ Revenue
Net Margin = Net Income ÷ Revenue

Download Data

Export ASBP earnings history in CSV or JSON format

Free sign-in required to download data

Aspire Biopharma Holdings, Inc. (ASBP) Earnings Overview

As of March 5, 2026, Aspire Biopharma Holdings, Inc. (ASBP) reported trailing twelve-month net income of -$32M. The company earned $-0.64 per diluted share over the past four quarters.

Looking at the long-term picture, ASBP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$359,071 in fiscal 2023.

Aspire Biopharma Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to industry peers including CAI (-$538M net income, -0.7% margin), VCYT ($66M net income, 0.1% margin), ADPT (-$80M net income, -0.9% margin), ASBP has comparable earnings metrics. Compare ASBP vs CAI →

Peer Comparison

Earnings metrics vs industry competitors

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ASBP logoASBPCurrent
-$32M$-0.64---—
CAI logoCAI
-$538M$-0.32-0.7%-0.9%-0.2%
VCYT logoVCYT
$66M$0.820.1%0.1%+1.6%
ADPT logoADPT
-$80M$-0.49-0.9%-0.6%+0.3%
NAUT logoNAUT
-$63M$-0.50--0.3%+0.2%
CDIO logoCDIO
-$7M$-3.73-240.3%-1.3%+0.5%
Best in group
Lowest in group

Historical Data

3 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2024-$13M-3391.6%-$3M$-0.26--
2023$-359,071+39.9%$-358,590$-0.01--
2022$-597,117-$-596,491$-0.01--

See ASBP's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ASBP Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare ASBP vs LLY

See how ASBP stacks up against sector leader Eli Lilly and Company.

Start Comparison

Frequently Asked Questions

Is ASBP growing earnings?

ASBP TTM EPS: $-0.64. Net income: $-32M. Earnings growth: N/A.

What are ASBP's profit margins?

Aspire Biopharma Holdings, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.

How consistent are ASBP's earnings?

ASBP earnings data spans 2022-2024. The current earnings trend is N/A YoY. Historical data enables comparison across business cycles.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.

Earnings Over Time

Net income and EPS trends